Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenx SE stock logo
ARGX
argenx
$645.14
+2.5%
$597.55
$352.77
$678.21
$39.39B0.6308,901 shs319,782 shs
Biogen Inc. stock logo
BIIB
Biogen
$121.08
+0.8%
$131.39
$110.04
$238.00
$17.72B0.061.35 million shs1.53 million shs
BioNTech SE stock logo
BNTX
BioNTech
$104.15
+0.1%
$100.82
$76.53
$131.49
$24.99B1.07909,960 shs872,391 shs
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$64.91
+2.2%
$59.94
$52.96
$72.50
$30.40B0.9130,486 shs19,692 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenx SE stock logo
ARGX
argenx
+2.48%+8.49%+9.00%-3.09%+71.81%
Biogen Inc. stock logo
BIIB
Biogen
+0.76%+2.46%-11.52%-17.20%-43.64%
BioNTech SE stock logo
BNTX
BioNTech
+0.14%-9.41%+14.38%-13.84%+17.26%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
+2.17%+4.21%+11.26%+12.85%+17.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenx SE stock logo
ARGX
argenx
2.5166 of 5 stars
2.52.00.00.04.11.71.9
Biogen Inc. stock logo
BIIB
Biogen
4.6901 of 5 stars
4.23.00.03.72.62.51.9
BioNTech SE stock logo
BNTX
BioNTech
2.379 of 5 stars
4.42.00.00.02.20.80.0
Novozymes A/S stock logo
NVZMY
Novozymes A/S
2.1857 of 5 stars
0.03.02.50.01.80.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenx SE stock logo
ARGX
argenx
2.91
Moderate Buy$699.288.39% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.38
Hold$201.9366.77% Upside
BioNTech SE stock logo
BNTX
BioNTech
2.89
Moderate Buy$143.4437.72% Upside
Novozymes A/S stock logo
NVZMY
Novozymes A/S
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest NVZMY, ARGX, BNTX, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2025
Biogen Inc. stock logo
BIIB
Biogen
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$210.00 ➝ $199.00
4/29/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$135.00 ➝ $115.00
4/28/2025
Biogen Inc. stock logo
BIIB
Biogen
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$118.00
4/28/2025
Biogen Inc. stock logo
BIIB
Biogen
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/25/2025
Biogen Inc. stock logo
BIIB
Biogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/23/2025
Biogen Inc. stock logo
BIIB
Biogen
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$219.00 ➝ $197.00
4/22/2025
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$221.00 ➝ $225.00
4/17/2025
argenx SE stock logo
ARGX
argenx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$681.00 ➝ $796.00
4/16/2025
Biogen Inc. stock logo
BIIB
Biogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/11/2025
argenx SE stock logo
ARGX
argenx
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00 ➝ $715.00
4/9/2025
Biogen Inc. stock logo
BIIB
Biogen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$157.00 ➝ $152.00
(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenx SE stock logo
ARGX
argenx
$2.19B17.99N/AN/A$69.22 per share9.32
Biogen Inc. stock logo
BIIB
Biogen
$9.68B1.83$19.88 per share6.09$114.71 per share1.06
BioNTech SE stock logo
BNTX
BioNTech
$2.75B9.08$4.48 per share23.25$92.17 per share1.13
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$2.60B11.70$0.89 per share72.83$4.45 per share14.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenx SE stock logo
ARGX
argenx
-$295.05M$12.59N/A59.46N/A-2.11%-1.45%-1.29%5/8/2025 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$11.1910.827.331.5116.87%14.98%8.76%5/1/2025 (Estimated)
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.00N/AN/AN/A-15.16%-2.35%-2.05%5/5/2025 (Estimated)
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$439.08M$1.5841.0830.333.87N/AN/AN/A5/1/2025 (Estimated)

Latest NVZMY, ARGX, BNTX, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
argenx SE stock logo
ARGX
argenx
$0.98N/AN/AN/A$748.34 millionN/A
5/5/2025Q1 2025
BioNTech SE stock logo
BNTX
BioNTech
-$2.68N/AN/AN/A$175.90 millionN/A
5/1/2025Q1 2025
Biogen Inc. stock logo
BIIB
Biogen
$3.59N/AN/AN/A$2.25 billionN/A
3/10/2025Q4 2024
BioNTech SE stock logo
BNTX
BioNTech
$0.38$1.08+$0.70$1.15$1.24 billion$1.19 billion
2/27/2025Q4 2024
argenx SE stock logo
ARGX
argenx
$0.98$1.58+$0.60$11.79$678.52 million$761.22 million
2/12/2025Q4 2024
Biogen Inc. stock logo
BIIB
Biogen
$3.43$3.44+$0.01$1.83$2.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenx SE stock logo
ARGX
argenx
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
BioNTech SE stock logo
BNTX
BioNTech
$1.531.47%N/AN/A N/A
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$0.751.16%N/A47.47%N/A

Latest NVZMY, ARGX, BNTX, and BIIB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/10/2025
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$0.37584/7/20254/7/20254/23/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenx SE stock logo
ARGX
argenx
N/A
8.53
7.88
Biogen Inc. stock logo
BIIB
Biogen
0.27
1.35
0.90
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Novozymes A/S stock logo
NVZMY
Novozymes A/S
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
argenx SE stock logo
ARGX
argenx
60.32%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.03%

Insider Ownership

CompanyInsider Ownership
argenx SE stock logo
ARGX
argenx
2.43%
Biogen Inc. stock logo
BIIB
Biogen
0.16%
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
argenx SE stock logo
ARGX
argenx
65061.06 million59.29 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
8,720146.38 million146.14 millionOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080239.97 million193.71 millionOptionable
Novozymes A/S stock logo
NVZMY
Novozymes A/S
6,756468.30 millionN/ANot Optionable

Recent News About These Companies

Novozymes A/S stock logo
Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update
Novonesis price target lowered to DKK 490 from DKK 500 at Barclays
Invitation to the Annual General Meeting
Novonesis (Novozymes) B ADR
Novonesis: Still Too Expensive
Novonesis added to European Conviction List at Goldman Sachs
Novonesis Reports Strong Q3 Growth in 2024
What Wall Street expects from Novozymes A-S (B)'s earnings
Novozymes A-S (B) Un earnings: here's what to expect

New MarketBeat Followers Over Time

Media Sentiment Over Time

argenx stock logo

argenx NASDAQ:ARGX

$645.14 +15.63 (+2.48%)
As of 04/30/2025 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Biogen stock logo

Biogen NASDAQ:BIIB

$121.08 +0.91 (+0.76%)
As of 04/30/2025 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$104.15 +0.15 (+0.14%)
As of 04/30/2025 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Novozymes A/S stock logo

Novozymes A/S OTCMKTS:NVZMY

$64.91 +1.38 (+2.17%)
As of 04/30/2025 03:59 PM Eastern

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.